

## SPDR<sup>®</sup> S&P<sup>®</sup> Pharmaceuticals ETF

ISIN US78464A7220

### Fund Objective

The SPDR<sup>®</sup> S&P<sup>®</sup> Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P<sup>®</sup> Pharmaceuticals Select Industry<sup>®</sup> Index.

Ordinary brokerage commissions may apply.

### About This Benchmark

The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The pharmaceuticals segment of the S&P TMI comprises the Pharmaceuticals sub-industry.

**Index Ticker** SPSIPHTR

**Index Type** Total Return

### Key Facts

#### Inception Date

16-Jun-2006

#### Domicile

United States

#### Index

S&P Pharmaceuticals Select Industry Index

#### Income Treatment

Distribution

#### Base Currency

USD

#### Legal Structure

1940/33 Act

#### Investment Manager

SSGA Funds Management, Inc.

#### Replication Method

Replicated

#### Gross Expense Ratio

0.35%

**Countries of Permissible for Marketing** United States, Switzerland

### Listings

| Exchange                  | Exchange Ticker | Trading Currency | iNAV Ticker | Reuters Code |
|---------------------------|-----------------|------------------|-------------|--------------|
| *NYSE ARCA EXCHANGE       | XPH             | USD              | XPHIV       | XPH.P        |
| Bolsa Mexicana de Valores | XPH             | MXN              | -           | -            |

\*Denotes Primary Listing

### Performance

| Total Return | NAV % | MARKET VALUE % | Index % | Annualised | NAV % | MARKET VALUE % | Index % |
|--------------|-------|----------------|---------|------------|-------|----------------|---------|
| 1 Month      | 8.86  | 8.88           | 8.91    | 1 Year     | 14.39 | 14.44          | 14.59   |
| 3 Month      | 19.82 | 19.90          | 19.95   | 3 Year     | 6.82  | 6.82           | 7.00    |
| YTD          | 14.39 | 14.44          | 14.59   | 5 Year     | 0.95  | 0.96           | 1.09    |
|              |       |                |         | 10 Year    | 10.74 | 10.73          | 10.93   |

### Fund Characteristics

|                    |       |                        |             |
|--------------------|-------|------------------------|-------------|
| Number of Holdings | 42    | Average Price/Book     | 3.25        |
| Dividend Yield     | 0.53% | Average Market Cap (M) | \$56,075.96 |

Source: SSGA, 31 December 2020.

Characteristics are subject to change.

**Performance quoted represents past performance, which is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. The performance data does not take account of the commissions and costs incurred on the issue and redemption, or purchases and sale, of units. Visit [ssga.com](http://ssga.com) for most recent month-end performance.**

**Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index.**

The performance is calculated in USD, its value may rise or fall as a result of currency fluctuations.

**Definitions:** **NAV** - The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding. **Market Value** - Determined by the midpoint between the bid/offer prices as of the closing time of the New York Stock Exchange (typically 4:00PM EST) on business days. **Gross Expense Ratio** - The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus. **Dividend Yield** - The sum of the most recent 12 dividends within the past 365 days divided by Net Asset Value per share, expressed as a percentage. **Average Price/Book Ratio** - The weighted harmonic average of closing market price divided by the most recent reported book value for each security in the fund's portfolio as calculated for the last twelve months.

| Top Holdings*                | Weight % | Sector Breakdown* | Weight % |
|------------------------------|----------|-------------------|----------|
| Royalty Pharma Plc Class A   | 4.94     | Pharmaceuticals   | 100.00   |
| Jazz Pharmaceuticals Plc     | 4.75     |                   |          |
| Catalent Inc                 | 4.58     |                   |          |
| Viatrix Inc.                 | 4.53     |                   |          |
| Elanco Animal Health Inc.    | 4.48     |                   |          |
| Eli Lilly and Company        | 4.42     |                   |          |
| Zoetis Inc. Class A          | 4.35     |                   |          |
| Johnson & Johnson            | 4.31     |                   |          |
| Bristol-Myers Squibb Company | 4.28     |                   |          |
| Merck & Co. Inc.             | 4.13     |                   |          |

Source: SSGA, 31 December 2020.

\* Are subject to change.

#### For More Information

Visit our website at [www.ssga.com](http://www.ssga.com).

Contact our SPDR ETF Sales and Support team at [spdrseurope@ssga.com](mailto:spdrseurope@ssga.com) or call your local SPDR ETF representative.

Switzerland: +41 (0) 44 245 7000

#### Marketing Communication:

##### For Professional Investor Client/Qualified Investor Use Only in the Switzerland. Not for public distribution.

This document has been issued by State Street Global Advisors Limited ("SSGA"). Authorised and regulated by the Financial Conduct Authority. Registered No. 2509928. VAT No. 5776591 81. Registered office: 20 Churchill Place, Canary Wharf, London, E14 5HJ. Telephone: 020 3395 6000. Facsimile: 020 3395 6350 Web: [www.ssga.com](http://www.ssga.com).

##### NOTICETO PERSONS IN THE EUROPEAN ECONOMIC AREA ("EEA")

The fund is permitted to market into the relevant EEA jurisdiction pursuant to either Article 42 of AIFMD (if and as implemented under national laws of such member state); or (ii) can otherwise be lawfully offered or sold (including on the basis of an unsolicited request from a professional client/qualified investor).

**The fund is an alternative investment fund for the purpose of the European Union Alternative Investment Fund Managers Directive (Directive 2011/61/EU) ("AIFMD"). SSGA Funds Management, Inc. or State Street Global Advisors Trust Company is the alternative investment fund manager ("AIFM") of the fund.**

**For Switzerland Qualified Investor:** The distribution of interests of U.S. SPDR ETFs in Switzerland will be exclusively made to, and directed at, qualified investors. The legal documents of U.S. SPDR ETFs can be obtained free of charge from the representative in Switzerland. Swiss Representative & Swiss Paying Agent: State Street Bank International GmbH Beethovenstrasse 19 8027 Zurich, Switzerland Tel: +41 44 560 5000

SSGA Funds Management, Inc. serves as the investment advisor to the SPDR ETFs that are registered with the United States Securities and Exchange Commission under the Investment Company Act of 1940. SSGA Funds Management, Inc. is an affiliate of State Street Global Advisors Limited.

The information provided does not constitute investment advice as such term is defined under the Markets in Financial Instruments Directive (2014/65/EU) and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell any investment. It does not take into account any investor's or potential investor's particular investment objectives, strategies, tax status, risk appetite or investment horizon. If you require investment advice you should consult your tax and financial or other professional advisor.

##### Key/Investment Risk Disclosures:

**Capital at risk.** Investing involves risk including the risk of loss of principal.

**Equity securities** may fluctuate in value in response to the activities of individual companies and general market and economic conditions.

**Foreign Securities** may be subject to greater political, economic, environmental, credit and information risks. Foreign securities may be subject to higher volatility than U.S. securities, due to varying degrees of regulation and limited liquidity.

**Non-diversified funds** that focus on a relatively small number of securities tend to be more volatile than diversified funds and the market as a whole.

**Passively managed funds** hold a range of securities that, in the aggregate, approximates the full Index in terms of key risk factors and other characteristics.

ETFs trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Brokerage commissions and ETF expenses will reduce returns.

Because of their narrow focus, **sector funds** tend to be more volatile than broadly diversified funds and generally result in greater price fluctuations than the overall market.

Standard & Poor's, S&P and SPDR are registered trademarks of Standard & Poor's Financial Services LLC (S&P); Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC (Dow Jones); and these trademarks have been licensed for use by S&P Dow Jones Indices LLC (SPDJL) and sublicensed for certain purposes by State Street Corporation. State Street Corporation's financial products are not sponsored, endorsed, sold or promoted by SPDJL, Dow Jones, S&P, their respective affiliates and third party licensors and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability in relation thereto, including for any errors, omissions, or interruptions of any index.

**Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus which contains this and other information, visit [ssga.com](http://ssga.com) or talk to your financial advisor. Read it carefully before investing.**

The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without SSGA's express written consent.